LOS ANGELES, CA / ACCESSWIRE / August 18, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Sinovac Biotech Ltd. (''Sinovac'' or the ''Company'') (SVA) for possible violations of federal securities laws from April 30, 2013 through May 16, 2017 inclusive (the ''Class Period''). Investors who purchased or otherwise acquired Sinovac shares during the Class Period should contact the firm prior to the September 1, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO Weidong Yin bribed a member of China's Food and Drug Administration to assist Sinovac's vaccine clinical trial and approval; that this conduct would subject the Company to heightened regulatory scrutiny; and that as a result of the above, Sinovac's public statements were materially false and misleading at all relevant times. When this news became public, Sinovac's stock price decreased materially, which caused investors harm according to the Complaint.

Lundin Law PC was established by Brian Lundin, a securities litigator in Los Angeles dedicated to upholding the rights of shareholders.

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC